Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos, DREAMM-7 study investigators [m.in.] [AUT.] KRZYSZTOF GIANNOPOULOS, MARTA MORAWSKA, FRANCISZEK BURDAN, NORBERT GRZĄŚKO, PAULINA WŁASIUK. Lancet Oncol. [online] 2025 vol. 26 nr 8 s. 1067-1080, bibliogr. poz. 32. DOI: 10.1016/S1470-2045(25)00330-4